Format: Non-interactive recorded webinar with videos
1.0 CE Credits Available Until: November 2, 2021
*One hour of this webinar was presented at the ONS Bridge Conference
Target Audience
Social workers and other healthcare professionals involved in the care of patients with hematologic malignancies.
Course Content Level for Social Workers - All levels
Description
Nurses from three cancer centers discuss the nurse's role in preparing patients and caregivers for the CAR T-cell treatment process, assessment, monitoring for and managing side effects, and communication with the patient's community healthcare team to transition patient care back. Following a patient from initial treatment discussion, participants will learn about patient care for the case. With CAR T-cell therapy and follow-up care expanding beyond the major centers, nurses are essential members of the treatment team.
Learning Objectives
At the conclusion of this program, participants will be able to:
- Provide an overview of chimeric antigen receptor (CAR) T-cell therapy and the blood cancers and solid tumors under study for treatment
- Explain the nurse's role in assessment, monitoring for and managing side effects of treatment
- Describe the nurse's role in preparing patients and family members about the CART process and potential side effects of treatment
- Address the need for communication with a patient’s community oncologist and healthcare team to transition care after CAR T-cell therapy
- Identify resources for the nurse, social worker and other HCPs to educate and support patients and caregivers
Faculty
Sherry Adkins, RN, MSN, CNS, ANP-C
The University of Texas
MD Anderson Cancer Center
Houston, TX
Heather DiFilippo, MSN, CRNP
University of Pennsylvania Health System
Philadelphia, PA
Ilene Galinsky, BSN, MSN, NP-C
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Boston, MA
Kathleen McDermott, RN, BSN, OCN®, BMTCN®
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Boston, MA
Continuing Education Information
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. LLS maintains responsibility for this course. ACE provider approval period: 12/10/2020-12/10/2023. Social workers completing this course receive 1.0 continuing education credit.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for this program. Social workers will receive 1.0 CE clinical contact hour for this activity.
Participants must attend the free webinar in its entirety, watch all videos, submit the online evaluation form, and complete and submit the online post-test with a passing score of 70% to earn credit. Once submitted, the certificate will be automatically generated as a PDF online.
Providers
This program is provided by The Leukemia & Lymphoma Society.
Supporters
This program is supported by Bristol Myers Squibb; Kite, A Gilead Company and Novartis Pharmaceuticals Corporation.
Participants gain access to the webinar via the registration button above. To view system requirements for this program, please click here.
For questions, concerns, or for assistance for people with disabilities or grievances, please contact ProfEducation@LLS.org